Breakthrough Research Identifies New Drug Targeting Inflammation In Diabetes Complications

Researchers from the University at Albany and New York University Grossman School of Medicine have made a significant discovery. They found a method to block a crucial cellular pathway that causes chronic inflammation and hinders wound healing in diabetic individuals. This finding could lead to new treatments targeting the root causes of both type 1 and type 2 diabetes.

The team developed a small-molecule drug that disrupts an intracellular chain reaction linked to diabetes complications. "Current treatments for diabetes primarily focus on slowing disease progression; however, they do not address the underlying inflammation that contributes to the complications of diabetes. Our findings point to a promising new pathway for treating diabetes in the future," stated Alexander Shekhtman, co-senior author and Professor at the Department of Chemistry and the RNA Institute, Albany.

In diabetic patients, harmful molecules called "advanced glycation end products (AGEs)" build up in body tissues. These molecules activate a cell surface sensor known as the "Receptor for Advanced Glycation End products (RAGE)". This activation triggers "Diaphanous-1" (DIAPH1), a molecular structure inside cells. Normally, DIAPH1 supports regular cell functions, but overstimulation leads to chronic inflammation, which can cause cardiovascular issues and slow wound healing.

Using structural biology techniques, researchers constructed a model to understand how RAGE activates DIAPH1. This model helped them identify a binding site on DIAPH1 that plays a role in this pathway. The discovery offers hope for developing therapies for both types of diabetes and designing markers to measure treatment effectiveness in live animals.

Shekhtman emphasized that these results could lead to therapies addressing both types of diabetes. The research also opens doors for creating markers that assess how well new treatments work in living organisms. By focusing on this pathway, scientists aim to tackle the inflammation contributing to diabetes complications directly.

The study's findings highlight an innovative approach by targeting cellular pathways involved in diabetes-related issues. This research could pave the way for more effective treatments that go beyond merely slowing disease progression, offering hope for better management of diabetes complications in the future.

With inputs from WAM